MLTX - Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today? | Benzinga
On Sunday, MoonLake Immunotherapeutics (NASDAQ:MLTX) announced that continued treatment with Nanobody sonelokimab led to significant improvements across all key outcomes at 24-week data from the ARGO trial in psoriatic arthritis (PsA).
The 207-patient ARGO trial demonstrated that the primary endpoint, the American College of Rheumatology (ACR) 50, continued to improve from week 12 and exceeded 60% by week 24.
The more rigorous ACR70 outcome was achieved by approximately 40% of patients by week 24.
In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, ...